Three major institutional investors maintain substantial positions in PTC Therapeutics as the company navigates regulatory approvals and setbacks across its rare disease portfolio. Vanguard and BlackRock anchor the shareholder base through passive exposure, while healthcare specialist Armistice Capital holds a concentrated active stake reflecting conviction in the company’s clinical execution.

Institutional Ownership Patterns Reveal Diverse Investment Approaches

Vanguard Group holds the largest disclosed position with 8.61 million shares as of March 31, 2025. BlackRock filed an amended Schedule 13G on April 17, 2025, disclosing 6,274,384 shares representing roughly 8% of outstanding stock.

Armistice Capital reported 5,434,843 shares in a Schedule 13G/A amendment filed May 15, 2025, e

See Full Page